Conferences ICAAC 2014
Other Infections
Coverage of IDWeek 2014
- Details
- Category: HIV Treatment
- Published on Friday, 17 October 2014 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of IDWeek 2014, October 8-12, in Philadelphia.
Conference highlights include the HIV cascade of care, experimental antiretroviral therapies, interferon-free hepatitis C treatment, and news about other infectious diseases including Ebola virus and enterovirus D68.
Full listing of coverage by topic
10/17/14
HCV Sexual Transmission: HIV Negative May Be at Risk, More Awareness and Testing Needed
- Details
- Category: HCV Sexual Transmission
- Published on Friday, 10 October 2014 00:00
- Written by Liz Highleyman
Hepatitis C virus (HCV) is known to be sexually transmitted among HIV positive men who have sex with men, but HIV negative men may be at risk as well, according to recent reports. Other recent studies have looked at awareness of HCV sexual transmission and screening practices, suggesting that improvement is needed in both areas.
ICAAC 2014: Stribild Works Well Regardless of Age, Sex, or Race/Ethnicity
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 23 September 2014 00:00
- Written by Liz Highleyman
The elvitegravir-based Stribild single-tablet regimen demonstrated good long-term efficacy and tolerability -- including fewer neuropsychiatric side effects than Atripla -- with consistent results across demographic subgroups, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this month in Washington, DC. Other studies showed that Stribild is a good option for black patients either initiating or switching antiretroviral therapy (ART).
ICAAC 2014: Anal HPV Infection and Dysplasia Common in HIV+ Women and Gay Men
- Details
- Category: Human Papillomavirus (HPV)
- Published on Friday, 03 October 2014 00:00
- Written by Liz Highleyman
Anal infection with high-risk human papillomavirus (HPV) types was common among women with HIV in France, while a Spanish study found a low rate of pre-cancerous anal cell changes in HIV positive women compared with men who have sex with men, researchers reported at the recent 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, DC.
ICAAC 2014: Cobicistat Long-term Efficacy Matches Ritonavir as PI Booster
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 16 September 2014 00:00
- Written by Liz Highleyman
Long-term rates of viral suppression and side effects were similar among people using cobicistat and those using ritonavir as a booster for atazanavir (Reyataz), according to 3-year data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC. Another study found that cobicistat was well-tolerated by people with mild-to-moderate kidney impairment.
ICAAC 2014: IRIS and Risk of Early Death Among HIV+ People with Tuberculosis
- Details
- Category: Tuberculosis (TB)
- Published on Tuesday, 23 September 2014 00:00
- Written by Theo Smart
People coinfected with HIV and tuberculosis (TB) who go onto develop immune reconstitution inflammatory syndrome (IRIS) while on antiretroviral therapy (ART) have a pre-ART immunological profile that is easily distinguishable from those who are at risk of early mortality despite being treated for both HIV and TB, according to a presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this month in Washington, DC.
ICAAC 2014: Tenofovir Vaginal Ring and Nanoparticle Gel Are Protective in Animal Studies
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 16 September 2014 00:00
- Written by Liz Highleyman
A vaginal ring that dispenses tenofovir protected all 6 macaque monkeys exposed to an HIV-like virus, while a heat-sensitive vaginal gel containing tenofovir nanoparticles prevented infection of mice, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC.
ICAAC 2014: Telaprevir and Boceprevir Have Limited Efficacy in Real-world Use
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 23 September 2014 00:00
- Written by Liz Highleyman
Hepatitis C treatment using the first-generation HCV protease inhibitors telaprevir (Incivek or Incivo) or boceprevir (Victrelis) cured only 71% of people with easier-to-treat HCV genotypes 1b, falling to 47% for those with genotype 1a, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this month in Washington, DC.
ICAAC 2014: Antibiotic Stewardship Programs Reduce Use and Improve Outcomes
- Details
- Category: Other Health News
- Published on Tuesday, 16 September 2014 00:00
- Written by American Society for Microbiology
Programs to promote appropriate use of antibiotics in hospitals and other healthcare facilities can help reduce use of these drugs and thereby ameliorate the risk of developing resistance, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC.
More Articles...
- ICAAC 2014: New Drug Isavuconazole Is Effective Against Opportunistic Fungal Infections
- ICAAC 2014: Delafloxacin Shows Promise as a Single-dose Treatment for Gonorrhea
- ICAAC 2014: AbbVie 3D Hepatitis C Regimen Is Well-Tolerated in Phase 3 Trials
- ICAAC 2014: NRTI BMS-986001 Safe and Effective, but Associated with Resistance
- ICAAC 2014: PK Study Shows Feasibility of Long-acting Integrase Inhibitor Cabotegravir
- ICAAC 2014: Single Dose of Flu Drug Peramavir Looks Safe and Effective
- Coverage of the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy
- ICAAC 2014: New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones
- ICAAC 2014: Sangamo Provides Update on Gene Therapy to Protect T-cells From HIV
- ICAAC 2014: Attempt to Shorten Standard Tuberculosis Treatment Fails in REMoxTB Trial
- ICAAC 2014: AbbVie 3D Regimen Shows High Cure Rates for Genotype 1b HCV Patients
- ICAAC 2014: AbbVie 3D Combination Works Well for People with HIV/HCV Coinfection
Web Design and Development by